Idacta mAb INT-001 represents an exciting clinical method for combating specific blood-related tumors. This particular antigen-binding protein shows the unique mode of effect, mainly binding to the CD38 antigen, a https://socialmediainuk.com/story26567920/idacta-mab-int-001-a-innovative-antibody-under-testing